Ordering RecommendationRecommendations when to order or not order the test. May include related or preferred tests.
Confirm infectious agent as C. burnetii (Q-fever) in symptomatic patients. Recommend testing of acute and convalescent sera.
MnemonicUnique test identifier.
QF G 1/2
MethodologyProcess(es) used to perform the test.
Semi-Quantitative Indirect Fluorescent Antibody
PerformedDays of the week the test is performed.
Mon, Wed, Fri
ReportedExpected turnaround time for a result, beginning when ARUP has received the specimen.
1-6 days
New York DOH Approval StatusIndicates test has been approved by the New York State Department of Health.
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect
Serum separator tube (SST).
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL) Parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimens. Mark specimens plainly as "acute" and "convalescent."
Storage/Transport Temperature
Refrigerated.
Unacceptable Conditions
Contaminated, hemolyzed, or severely lipemic specimens.
Remarks
Stability
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Reference IntervalNormal range/expected value(s) for a specific disease state. May also include abnormal ranges.
Test Number
Component
Reference Interval
C. burnetii (Q-Fever) Ab, Phase I IgG
Negative
C. burnetii (Q-Fever) Ab, Phase II IgG
Negative
Interpretive DataBackground information for test. May include disease information, patient result explanation, recommendations, details of testing, associated diseases, explanation of possible patient results.
Single phase II IgG titers of 1:256 and greater are considered evidence of C. burnetii infection at some time prior to the date of the serum specimen. Phase I antibody titers of 1:16 and greater are consistent with chronic infection or convalescent phase of Q-fever.
Compliance Category
FDA
NoteAdditional information related to the test.
If either C. Burnetii Abs IgG Phase I and/or Phase II result is indeterminate or positive, then titer(s) will be added. Additional charges apply.
CPT CodesThe American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
AliasesOther names that describe the test. Synonyms.
Coxiella burnetii
Coxiella Titer
Q Fever Phases I and II antibody
Coxiella burnetii (Q-Fever) Antibody IgG, Phase I and II with Reflex to Titer
Chat
Feedback
